Clinical Trial

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

Study acronym: NADIM-ADJUVANT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an open-label, randomised, two-arm, phase III, multi-centre clinical trial. 210 stage IB-IIIA, completely resected, non-small cell lung cancer patients will be enrolled in this trial to evaluate the disease free survival between experimental arm (Adjuvant Chemotherapy-Immunotherapy + maintenance adjuvant Immunotherapy) and control arm (Adjuvant Chemotherapy)
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-09-21; most recent amendment 2026-04-29.
Status change: Recruiting → Active, Not Recruiting 2024-01-17
Status change: Not Yet Recruiting → Recruiting 2021-02-01
Trial Details
NCT Number NCT04564157
Lead Sponsor Fundación GECP
Conditions Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
Enrollment 210 participants
Start Date 2021-01-13
Primary Completion 2030-04-01 (estimated)
Study Completion 2031-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-05